Stocks TelegraphStocks Telegraph
Stock Ideas

LIPO Financial Statements and Analysis

NASDAQ : LIPO

Lipella Pharmaceuticals Inc.

$4.65
2.03+77.48%
At Close 4:00 PM
$4.28
-0.37-7.96%
After-Market 06:48 PM
60.03
ESG ScoreESG Rating

LIPO FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

LIPO Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue80.38K136.431M145.88K120.842K104.051M
cost of revenue1.047M661.558K72.00723.00833.26K
gross profit-966.313K135.769M145.808K120.119K103.218M
gross profit ratio-12.0220.9951.000.9940.992
research and development expenses00842.60K454.20K833.26M
general and administrative expenses493.102M427.062K520.926K396.236K627.518K
selling and marketing expenses-492.609M0-520.405M-2.155B0
selling general and administrative expenses493.102K427.062K520.854K395.513K627.518K
other expenses0-136.431K0830.053M0
operating expenses493.102K290.631K1.363M849.713K523.467K
cost and expenses1.54M952.189K1.364M850.436K1.357M
interest income14.778K14.043K25.837K40.71K33.157K
interest expense000-10.859M0
depreciation and amortization722.001.371K72.00723.0033.157K
ebitda-1.444M-936.775K-1.192M-728.87K-1.324M
ebitda ratio-17.964-0.007-8.346-6.032-0.013
operating income-1.459M-952.189K-1.218M-729.59K-1.357M
operating income ratio-18.156-0.007-8.347-6.038-0.013
total other income expenses net-1.443B14.043K25.837K40.706K33.157M
income before tax-1.445B-938.146K-1.192M-688.884K-1.324M
income before tax ratio-17.973K-0.007-8.17-5.701-0.013
income tax expense00-2.00-58.388M33.124M
net income-1.445B-938.146M-1.192M-688.884K-1.324M
net income ratio-17.973K-6.876-8.17-5.701-0.013
eps-1.29-0.12-0.16-0.11-0.23
eps diluted-1.29-0.12-0.16-0.11-0.23
weighted average shs out1.119M7.606M7.292M6.054M5.754M
weighted average shs out dil1.119M7.606M7.292M6.054M5.754M
Graph

LIPO Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents1.354M1.187M2.105M3.294M2.41M
short term investments1.352B0000
cash and short term investments1.354B1.187M2.105M3.294M2.41M
net receivables31.079K35.332K68.934K32.286K53.14K
inventory0000-261.012M
other current assets726.231M858.989K836.857K103.256K261.22M
total current assets2.08B2.081M3.011M3.429M2.671M
property plant equipment net80.141K103.285K126.067K147.894K169.878K
goodwill00000
intangible assets00000
goodwill and intangible assets00000
long term investments00000
tax assets00000
other non current assets000-1.000
total non current assets80.141K103.285K126.067K147.893K169.878K
other assets80.06M001.000
total assets2.16B2.184M3.137M3.577M2.841M
account payables459.453K178.361K293.835K138.016K303.052K
short term debt70.83K93.679K91.705K89.223K87.272K
tax payables00000
deferred revenue0000-158.248M
other current liabilities170.903K208.273K166.341K158.116K158.406M
total current liabilities701.186K480.313K551.881K385.355K548.73K
long term debt0023.997K47.371K70.484K
deferred revenue non current00000
deferred tax liabilities non current00000
other non current liabilities1.001.00000
total non current liabilities1.001.0023.997K47.371K70.484K
other liabilities700.485M-1.00000
capital lease obligations70.83K93.679K23.997K47.371K157.756K
total liabilities701.186M480.313K575.878K432.726K619.214K
preferred stock00000
common stock109.00761.00704.00605.00580.00
retained earnings-13.898M-12.454M-11.516M-10.324M-9.635M
accumulated other comprehensive income loss00000
other total stockholders equity15.357M14.157M14.076M13.468M11.856M
total stockholders equity1.459M1.704M2.561M3.144M2.222M
total equity1.459M1.704M2.561M3.144M2.222M
total liabilities and stockholders equity2.16M2.184M3.137M3.577M2.841M
minority interest00000
total investments1.352B0000
total debt70.83K93.679K115.702K136.594K157.756K
net debt-1.283M-1.093M-1.99M-3.157M-2.252M
Graph

LIPO Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-06-302024-03-312023-12-312023-09-302023-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202320232023
periodQ2Q1Q4Q3Q2
deferred income tax00962.00-962.000
stock based compensation80.667K208.64K-1.355M298.759K847.618K
change in working capital-62.682K-605.342K-41.897K213.286K41.353K
accounts receivables33.602K-36.648K20.854K-25.096K55.923K
inventory0060.515K25.096K-55.923K
accounts payables-115.474K155.819K-165.036K280.995K-126.863K
other working capital19.19K-724.513K41.77K-67.709K168.216K
other non cash items165.279K289.613K1.354M122.162K-5.394K
net cash provided by operating activities-918.792K-1.388M-730.058K-689.363K-655.109K
investments in property plant and equipment00-14.42M-14.434K0
acquisitions net00000
purchases of investments00000
sales maturities of investments00000
other investing activites00000
net cash used for investing activites00-14.42M-14.434K0
debt repayment00-2.348K-2.281K-250.00K
common stock issued0200.00K1.612M00
common stock repurchased00000
dividends paid00000
other financing activites0200.00K4.696K0-250.00K
net cash used provided by financing activities0200.00K1.614M-2.281K-250.00K
effect of forex changes on cash00-2.281K2.281K0
net change in cash-918.793K-1.188M883.891K-703.797K-905.109K
cash at end of period1.187M2.105M3.294M2.41M3.114M
cash at beginning of period2.105M3.294M2.41M3.114M4.019M
operating cashflow-918.792K-1.388M-730.058K-689.363K-655.109K
capital expenditure00-14.42M-14.434K0
free cash flow-918.792K-1.388M-15.15M-703.797K-655.109K
Graph

Frequently Asked Questions

How did Lipella Pharmaceuticals Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, LIPO generated $80.38K in revenue last quarter, while its costs came in at $1.05M.

Last quarter, how much Gross Profit did Lipella Pharmaceuticals Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Lipella Pharmaceuticals Inc. reported a -$966.31K Gross Profit for the quarter ended Jun 30, 2024.

Have LIPO's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. LIPO incurred $493.10K worth of Operating Expenses, while it generated -$1.46M worth of Operating Income.

How much Net Income has LIPO posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Lipella Pharmaceuticals Inc., the company generated -$1.44B in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Lipella Pharmaceuticals Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Lipella Pharmaceuticals Inc. as of the end of the last quarter was $1.35M.

What are LIPO's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, LIPO had Total Net Receivables of $31.08K.

In terms of Total Assets and Current Assets, where did Lipella Pharmaceuticals Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of LIPO were $2.08B, while the Total Assets stand at $2.16B.

As of the last quarter, how much Total Debt did Lipella Pharmaceuticals Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of LIPO's debt was $70.83K at the end of the last quarter.

What were LIPO's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, LIPO reported total liabilities of $701.19M.

How much did LIPO's Working Capital change over the last quarter?

Working Capital Change for LIPO was -$62.68K over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

LIPO generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. LIPO generated -$918.79K of Cash from Operating Activities during its recently reported quarter.

What was LIPO's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. LIPO reported a -$918.79K Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph